BR112022008192A2 - Queratina bd-4, sua preparação e composições farmacêuticas e uso - Google Patents

Queratina bd-4, sua preparação e composições farmacêuticas e uso

Info

Publication number
BR112022008192A2
BR112022008192A2 BR112022008192A BR112022008192A BR112022008192A2 BR 112022008192 A2 BR112022008192 A2 BR 112022008192A2 BR 112022008192 A BR112022008192 A BR 112022008192A BR 112022008192 A BR112022008192 A BR 112022008192A BR 112022008192 A2 BR112022008192 A2 BR 112022008192A2
Authority
BR
Brazil
Prior art keywords
keratin
preparation
pharmaceutical compositions
antitussive
expectorant
Prior art date
Application number
BR112022008192A
Other languages
English (en)
Inventor
Yu Shishan
Wang Xiaoliang
Li Mi
Su Guozhu
Wang Ling
Cai Jie
Xu Shaofeng
Fu Jiang
Qu Jing
Original Assignee
Inst Materia Medica Cams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Materia Medica Cams filed Critical Inst Materia Medica Cams
Publication of BR112022008192A2 publication Critical patent/BR112022008192A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1748—Keratin; Cytokeratin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4741—Keratin; Cytokeratin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)

Abstract

QUERATINA BD-4, SUA PREPARAÇÃO E COMPOSIÇÕES FARMACÊUTICAS E USO. São fornecidos queratina BD-4, uma molécula de ácido nucleico que codifica a mesma, um vetor de expressão, uma célula hospedeira e uma composição farmacêutica contendo a queratina. A queratina BD-4 pode ser usada para preparar fármacos tendo efeitos antipiréticos, analgésicos, antitússicos, expectorantes e antiepilépticos.
BR112022008192A 2019-10-28 2020-10-28 Queratina bd-4, sua preparação e composições farmacêuticas e uso BR112022008192A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201911028740.5A CN112724229B (zh) 2019-10-28 2019-10-28 一种角蛋白bd-4、制法和其药物组合物与用途
PCT/CN2020/124329 WO2021083193A1 (zh) 2019-10-28 2020-10-28 一种角蛋白bd-4、制法和其药物组合物与用途

Publications (1)

Publication Number Publication Date
BR112022008192A2 true BR112022008192A2 (pt) 2022-07-12

Family

ID=75589395

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008192A BR112022008192A2 (pt) 2019-10-28 2020-10-28 Queratina bd-4, sua preparação e composições farmacêuticas e uso

Country Status (9)

Country Link
US (1) US20220372091A1 (pt)
EP (1) EP4053155A4 (pt)
JP (1) JP7402977B2 (pt)
KR (1) KR20220088737A (pt)
CN (2) CN112724229B (pt)
AU (1) AU2020373859A1 (pt)
BR (1) BR112022008192A2 (pt)
CA (1) CA3159335A1 (pt)
WO (1) WO2021083193A1 (pt)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85081A1 (fr) * 1983-11-09 1985-07-17 Oreal Medicament et composition medicamenteuse pour le traitement et/ou la prevention des maladies de la peau mettant en jeu un processus inflammatoire
JPH11146799A (ja) * 1997-09-10 1999-06-02 Snow Brand Milk Prod Co Ltd 新規プライマー及びその利用
US5994081A (en) * 1998-04-27 1999-11-30 Incyte Pharamaceuticals, Inc. Human keratins
WO1999064066A1 (fr) * 1998-06-09 1999-12-16 Shionogi & Co., Ltd. Agents induisant une tolerance immunitaire et contenant de la keratine dure ou une substance ressemblant a la keratine
CN1324859A (zh) * 2000-05-24 2001-12-05 上海博德基因开发有限公司 一种新的多肽——人角蛋白45.87和编码这种多肽的多核苷酸
US20070213717A1 (en) * 2006-02-14 2007-09-13 Sdgi Holdings, Inc. Biological fusion in the vertebral column
US8273702B2 (en) * 2006-02-17 2012-09-25 Wake Forest University Health Sciences Wound healing compositions containing keratin biomaterials
US20090047260A1 (en) * 2007-08-17 2009-02-19 Wake Forest University Health Sciences Keratin biomaterials for cell culture and methods of use
CN101647814A (zh) * 2008-08-13 2010-02-17 北京凯瑞创新医药科技有限公司 一种动物角的仿生酶解产物及其用途
CN102993291A (zh) * 2012-09-29 2013-03-27 乌仁套迪 双峰驼角蛋白、编码基因及其获取方法
CN105007894A (zh) * 2012-10-01 2015-10-28 天然化妆品有限公司 用于调节角蛋白材料的功能的植物脂质组合物、用于调节所述功能的方法和所述植物脂质的用途
CN104490929A (zh) * 2014-12-31 2015-04-08 蔺平 黄牛角的医药新用途
CN109078023B (zh) * 2018-09-17 2021-06-01 南京中医药大学 一种角质类中药有效部位及其制备方法与应用

Also Published As

Publication number Publication date
KR20220088737A (ko) 2022-06-28
EP4053155A4 (en) 2023-11-22
JP7402977B2 (ja) 2023-12-21
CN112724229A (zh) 2021-04-30
CN112724229B (zh) 2023-09-26
JP2022554305A (ja) 2022-12-28
EP4053155A1 (en) 2022-09-07
US20220372091A1 (en) 2022-11-24
CA3159335A1 (en) 2021-05-06
WO2021083193A1 (zh) 2021-05-06
CN114599669B (zh) 2023-12-22
AU2020373859A1 (en) 2022-06-09
CN114599669A (zh) 2022-06-07

Similar Documents

Publication Publication Date Title
UY38221A (es) Inhibidores de proteínas ras con g12c mutantes
ES2478264T3 (es) Glicerosomas y uso de estos en preparaciones farmacéuticas y cosméticas para aplicación tópica
SV2009002903A (es) Compuestos para la inhibicion de enzimas
CR8717A (es) Nuevos compuestos
DOP2010000387A (es) Compuestos pirazolicos 436
BR112023015045A2 (pt) Agonistas de receptores de gpcr, composições farmacêuticas que compreendem os mesmos e métodos para seu uso
BRPI0615292A8 (pt) composições e métodos para preparação de fármacos de má solubilidade em água com estabilidade aumentada
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
EA202091318A1 (ru) Препарат, содержащий аденовирус группы b
UY32203A (es) Amino pirimidinas y su uso en terapia
CL2004000897A1 (es) Uso de una toxina botulinica seleccionada del grupo que contiene los tipos a,b,c,d,e,f y g para preparar un medicamento util para controlar la cefalea sinusal a un paciente.
BR112015018087A8 (pt) composto, composição farmacêutica e uso
BR112018010271A2 (pt) material cristalino sintético emm-28, sua preparação e uso
BR112018002342A2 (pt) polímeros furtivos intrinsecamente desordenados e geneticamente modificados para entrega e métodos para uso dos mesmos
AR082688A1 (es) Uso de aglomerantes para preparar formulaciones estables al almacenamiento
BR112015010504A2 (pt) uso de inibidores de molécula pequena de malt1, método de identificação de um modulador de molécula pequena de malt1, e composição farmacêutica
CL2020002797A1 (es) Composiciones sólidas que comprenden un agonista de glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
CL2009001215A1 (es) Composiciones farmaceuticas que comprenden un primer agente seleccionado del grupo consistente de i) un agente antiinflamatorio, ii) acetaminofeno, iii) fenacetina, iv) tramadol, y un segundo agente; uso de dichas composiciones para tratar enfermedades proliferativas incluyendo cancer.
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
EA201990501A1 (ru) Фармацевтическая композиция
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
EA200701228A1 (ru) Стабильные композиции фенофибрата с эфирами жирных кислот
BR112022008192A2 (pt) Queratina bd-4, sua preparação e composições farmacêuticas e uso